CN114478717B - 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用 - Google Patents

一种重组新型冠状病毒蛋白疫苗、其制备方法和应用 Download PDF

Info

Publication number
CN114478717B
CN114478717B CN202210071951.2A CN202210071951A CN114478717B CN 114478717 B CN114478717 B CN 114478717B CN 202210071951 A CN202210071951 A CN 202210071951A CN 114478717 B CN114478717 B CN 114478717B
Authority
CN
China
Prior art keywords
asn
val
ser
tyr
phe
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202210071951.2A
Other languages
English (en)
Chinese (zh)
Other versions
CN114478717A (zh
Inventor
张学峰
靳玉琴
李启明
苏计国
梁宇
邵帅
张�浩
韩子泊
张靖
侯亚楠
陈实
杜丽芳
侯俊伟
马智静
雷泽华
郑凡
唐芳
刘兆明
刘宁
沈福杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China National Biotec Research Institute Co ltd
Original Assignee
China National Biotec Research Institute Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China National Biotec Research Institute Co ltd filed Critical China National Biotec Research Institute Co ltd
Priority to CN202210071951.2A priority Critical patent/CN114478717B/zh
Publication of CN114478717A publication Critical patent/CN114478717A/zh
Application granted granted Critical
Publication of CN114478717B publication Critical patent/CN114478717B/zh
Priority to PCT/CN2022/142936 priority patent/WO2023138333A1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202210071951.2A 2022-01-21 2022-01-21 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用 Active CN114478717B (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202210071951.2A CN114478717B (zh) 2022-01-21 2022-01-21 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
PCT/CN2022/142936 WO2023138333A1 (fr) 2022-01-21 2022-12-28 Vaccin recombinant à base de protéine sars-cov-2, son procédé de préparation et son utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210071951.2A CN114478717B (zh) 2022-01-21 2022-01-21 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用

Publications (2)

Publication Number Publication Date
CN114478717A CN114478717A (zh) 2022-05-13
CN114478717B true CN114478717B (zh) 2022-10-28

Family

ID=81472736

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210071951.2A Active CN114478717B (zh) 2022-01-21 2022-01-21 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用

Country Status (2)

Country Link
CN (1) CN114478717B (fr)
WO (1) WO2023138333A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478717B (zh) * 2022-01-21 2022-10-28 国药中生生物技术研究院有限公司 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113292640A (zh) * 2021-06-18 2021-08-24 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241493B2 (en) * 2020-02-04 2022-02-08 Curevac Ag Coronavirus vaccine
BR112022016054A2 (pt) * 2020-02-14 2022-10-11 Altimmune Inc Composições imunogênicas para coronavírus e usos das mesmas
CN113817029B (zh) * 2021-03-31 2022-09-23 国药中生生物技术研究院有限公司 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用
CN113461787A (zh) * 2021-04-28 2021-10-01 国药中生生物技术研究院有限公司 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
CN114478717B (zh) * 2022-01-21 2022-10-28 国药中生生物技术研究院有限公司 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113292640A (zh) * 2021-06-18 2021-08-24 国药中生生物技术研究院有限公司 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
SARS-CoV-2 Omicron variant: Characteristics and prevention;Xuemei He等;《MedComm》;20211216;第2卷(第4期);摘要、图4及第4.3节 *
Vaccine-escape and fast-growing mutations in the United Kingdom, the United States, Singapore, Spain, India, and other COVID-19-devastated countries;RuiWang等;《Genomics》;20210515;第133卷(第4期);摘要 *
冠状病毒疫苗的研究进展;崔文禹等;《微生物与感染》;20200825;第15卷(第04期);第199-205页 *
带你了解新冠疫苗混打及序贯免疫;綦佩妍;《中国国门时报》;20211025;第二部分及第三部分 *

Also Published As

Publication number Publication date
WO2023138333A1 (fr) 2023-07-27
CN114478717A (zh) 2022-05-13

Similar Documents

Publication Publication Date Title
CN113292640B (zh) 一种产生广谱交叉中和活性的重组新型冠状病毒rbd三聚体蛋白疫苗、其制备方法和应用
CN111560074B (zh) 一种基于幽门螺旋杆菌铁蛋白的新型冠状病毒s蛋白单区域亚单位纳米疫苗
CN114478718B (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
CN113817029B (zh) 一种新型冠状病毒s-rbd三聚体蛋白疫苗、其制备方法和应用
CN114315989A (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
JP6685903B2 (ja) 立体構造的に安定化されたｒｓｖ融合前ｆタンパク質
CN113185613A (zh) 新型冠状病毒s蛋白及其亚单位疫苗
CN115246874A (zh) 一种重组新型冠状病毒s-rbd三聚体蛋白、其制备方法和应用
CN117957016A (zh) Sars-cov-2与流感联合疫苗
CN107427571A (zh) 基于纳米颗粒的新型多价疫苗
CN107029227A (zh) 热稳定的呼吸道合胞病毒融合前 f 蛋白寡聚物及其在免疫组合物中的用途
JP2005523000A (ja) 多価連鎖球菌性ワクチン組成物および使用方法
CN114478717B (zh) 一种重组新型冠状病毒蛋白疫苗、其制备方法和应用
CN110746496B (zh) 一种鲍曼不动杆菌的pal重组蛋白及其编码基因和它们的应用
CN116478296B (zh) 截短的呼吸道合胞病毒f蛋白及其用途
CN108503696A (zh) 一种酵母细胞表达的寨卡病毒亚单位疫苗
CN116568324A (zh) 融合蛋白和疫苗
CN113773372A (zh) 重组蛋白及其制备方法和应用
WO2020068540A1 (fr) Compositions et procédés de fabrication et d'utilisation de particules de type viral (vlp)
CN103740736B (zh) 化学合成的HSV2病毒gE糖蛋白胞外区基因片段及其表达、应用
JP2008500802A5 (fr)
CN112250768B (zh) 牛副流感病毒重组抗原及其应用
CN113372454B (zh) 尼帕病毒受体结合糖蛋白及其应用
US20230106770A1 (en) Reagents and methods for preventing, treating or limiting severe acute respiratory syndrome (SARS) coronavirus infection
TW200844227A (en) Recombinant viral proteins and particles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40073046

Country of ref document: HK